@article{TEXTUAL,
      recid = {6032},
      author = {Ikegami, Sachie and Benirschke, Robert C. and Fakhrai-Rad,  Hossein and Motamedi, Mohammad H. and Hockett, Rick and  David, Sean and Lee, Hong Kee and Kang, Jason and Gniadek,  Thomas J.},
      title = {Target specific serologic analysis of COVID-19  convalescent plasma},
      journal = {PLOS ONE},
      address = {2021-04-28},
      number = {TEXTUAL},
      abstract = {<p>This study compared the performance of four serology  assays for Coronavirus Disease 2019 (COVID-19) and  investigated whether COVID-19 disease history correlates  with assay performance. Samples were tested at Northshore  using the Elecsys Anti-SARS-CoV-2 (Roche Diagnostics),  Access SARS-CoV-2 IgG anti-RBD (Beckman Coulter), and  LIAISON SARS-CoV-2 S1/S2 IgG (DiaSorin) as well as at  Genalyte using Maverick Multi-Antigen Serology Panel. The  study included one hundred clinical samples collected  before December 2019 and ninety-seven samples collected  from convalescent plasma donors originally diagnosed with  COVID-19 by PCR. COVID-19 disease history was self-reported  by the plasma donors. There was no difference in  specificity between the assays tested. Clinical sensitivity  of these four tests was 98% (Genalyte), 96% (Roche), 92%  (DiaSorin), and 87% (Beckman). The only statistically  significant differences in clinical sensitivity was between  the Beckman assay and both Genalyte and Roche assays.  Convalescent plasma donor characteristics and disease  symptoms did not correlate with false negative results from  the Beckman and DiaSorin assays. All four tests showed high  specificity (100%) and varying sensitivities (89–98%). No  correlations between disease history and serology results  were observed. The Genalyte Multiplex assay showed as good  or better sensitivity to three other previously validated  assays with FDA Emergency Use Authorizations.</p>},
      url = {http://knowledge.uchicago.edu/record/6032},
}